These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 2262558)

  • 1. Use of cytoplasmic 5'nucleotidase for differentiating malignant from benign monoclonal gammopathies.
    Majumdar G; Heard SE; Singh AK
    J Clin Pathol; 1990 Nov; 43(11):891-2. PubMed ID: 2262558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma.
    Dutoit JC; Vanderkerken MA; Anthonissen J; Dochy F; Verstraete KL
    Eur Radiol; 2014 Nov; 24(11):2754-65. PubMed ID: 25106487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal gammopathy of undetermined significance: a new proposal of workup.
    Mangiacavalli S; Cocito F; Pochintesta L; Pascutto C; Ferretti V; Varettoni M; Zappasodi P; Pompa A; Landini B; Cazzola M; Corso A
    Eur J Haematol; 2013 Oct; 91(4):356-60. PubMed ID: 23859528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Benign monoclonal gammopathy].
    Shirota T; Kondo M; Uchida H; Ito H
    Nihon Rinsho; 1995 Mar; 53(3):720-4. PubMed ID: 7699912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Utility of 8-colours multiparameter flow cytometry immunophenotyping of plasma cells for the management of monoclonal gammopathy].
    Gressier M; Chaquin M; Lhermitte L; Asnafi V; Macintyre E; Brouzes C
    Ann Biol Clin (Paris); 2013; 71(3):313-23. PubMed ID: 23747669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Plasma cell acid phosphatase in the differential diagnosis of monoclonal gammopathies].
    Milanesi B; Tafuri C; Perini M; Rota G; Peretti P
    Quad Sclavo Diagn; 1984 Jun; 20(2):149-54. PubMed ID: 6528014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of the bone marrow plasma cell cytoplasmic light chain ratio in differentiating between multiple myeloma and monoclonal gammopathy of undetermined significance.
    Majumdar G; Grace RJ; Singh AK; Slater NG
    Leuk Lymphoma; 1992 Dec; 8(6):491-3. PubMed ID: 1297481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple myeloma and multiple plasmacytomas associated with free gamma heavy chain, free kappa light chain and IgGk paraproteins: an unusual triple gammopathy.
    Deighan WI; O'Kane MJ; McNicholl FP; Keren DF
    Ann Clin Biochem; 2016 Nov; 53(6):706-711. PubMed ID: 27166317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?
    Sidiqi MH; Aljama M; Kumar SK; Jevremovic D; Buadi FK; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Fonder AL; Hobbs MA; Hwa YL; Kapoor P; Kourelis T; Leung N; Muchtar E; Lust JA; Kyle RA; Go RS; Rajkumar VS; Gertz MA; Dispenzieri A
    Blood Cancer J; 2020 May; 10(5):52. PubMed ID: 32376870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.
    Zingone A; Kuehl WM
    Semin Hematol; 2011 Jan; 48(1):4-12. PubMed ID: 21232653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the diagnosis and management of myeloma.
    Greipp PR
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):24-45. PubMed ID: 1509293
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma cell morphology in multiple myeloma and related disorders.
    Ribourtout B; Zandecki M
    Morphologie; 2015 Jun; 99(325):38-62. PubMed ID: 25899140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of aldehyde dehydrogenase in B-cell and plasma cell subsets of monoclonal gammopathy patients and healthy donors.
    Všianská P; Bezděková R; Kryukov F; Almáši M; Pour L; Penka M; Hájek R; Říhová L
    Eur J Haematol; 2017 Jan; 98(1):19-25. PubMed ID: 27199264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
    Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
    Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review.
    Cosemans C; Oben B; Arijs I; Daniëls A; Declercq J; Vanhees K; Froyen G; Maes B; Mebis J; Rummens JL
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):235-248. PubMed ID: 29506935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
    van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
    Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [50-year-old man with fatigue and monoclonal gammopaty].
    Raeder H; Kildahl-Andersen O; Stalsberg H
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2677-9. PubMed ID: 17972388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.